Breakthrough Innovation Gives Greater Numbers of Pharmaceutical Scientists Access to the Power of the Xevo TQ System's Quantitative and Qualitative
Capabilities
MILFORD, Mass., Nov. 13 /PRNewswire-FirstCall/ -- Focused on the process of helping firms to move promising drug candidates into commercialization, Waters Corporation (NYSE: WAT) will showcase innovative UltraPerformance LC(R) (UPLC) and mass spectrometry (MS) solutions at the American Association of Pharmaceutical Scientists Annual Meeting and Exposition (AAPS), November 16 - 20 in Atlanta, Georgia.
With the cost of developing and commercializing new drugs at an all-time high, there is an acute need for versatile and multitasking analytical instruments that can automate routine tasks and obtain more analytical data faster with a minimum of effort. Waters(R) goal is to allow pharmaceutical scientists to devote more precious time to value-added, problem-solving activities that lie at the heart of the drug discovery process.
Leading Waters' offerings at AAPS is the Xevo(TM) TQ MS System, an advanced tandem quadrupole mass spectrometer that allows more pharmaceutical scientists across disciplines to quickly assess the candidacy of promising new entities. Aided by the instrument's IntelliStart(TM) and ScanWave(TM) technologies, the Xevo TQ MS System produces high-quality mass spectral data at UPLC(R) acquisition speeds without sacrificing data quality. With tools like the Xevo TQ MS System, increases in information per unit of time -- and in the value of that information -- promise to greatly enhance efforts to "industrialize" the process of drug discovery on a global basis.
Waters Scientific Seminars at AAPS
Waters UP
'/>"/>
| SOURCE Waters Corporation Copyright©2008 PR Newswire. All rights reserved |